Premier Biomedical Inc (OTCMKTS:BIEI) Heats Up

1

Premier Biomedical Inc (OTCMKTS:BIEI) is making another explosive move up on huge volume as the Company continues to put out some big press. The stock exploded off its $0.0023 lows last month and has established itself as a volume leader in recent weeks.

CEO William A. Hartman has certainly helped the cause with statements such as ”I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis.” BIEI has also been the subject of unprecedented inside buying in recent months.

Premier Biomedical Inc (OTCMKTS:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for neurofibromatosis, atherosclerosis and muscular dystrophy. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent.

Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.

Premier Biomedical, Inc. is developing a methodology for treating multiple diseases, such as cancer, which is completely different from the standard treatments now being utilized. The vast majority of presently known treatments directly inject possibly harmful agents into the body of a patient. This presents a very real risk of adverse side effects from the treatment.

BIEI proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects. We believe this method could be superior to current treatments which counteract symptoms or eliminate the presence of most illnesses, but often are accompanied by catastrophic or even fatal side effects. Premier’s “Subtractive” therapy is designed to eliminate the etiology agent(s) or modify the pathophysiological changes brought about by certain diseases, thereby reducing risks associated with conventional “Additive” therapy (i.e., adding chemicals to the body).

The initial disease target is breast cancer, however, we believe this same methodology can also be applied in the future to treating other forms of cancer, Leukemia, Muscular Dystrophy, Cockayne Syndrome, Neurofibromatosis, Fibromyalgia, and Atherosclerosis. Collectively, these diseases represent over $700 billion in annual treatment costs today. This is a tremendous market opportunity for Premier’s methodology, and, many of these diseases can be orphan drug designated (regulatory fast track).

Premier has developed a proprietary patented drug candidate, Feldetrex™. Based on our initial studies, we found Feldetrex™ to be another promising option for the comprehensive management of muscular and neuropathic pain, as well as chemical addiction. This unique drug combination is expected to deliver significant relief to patients, while presenting fewer, if any, side effects than alternate medications currently available. The annual market size for all proposed market segments for Feldetrex™ is over $20 Billion. The company strategy is to use the sales of Feldetrex™ to provide short term revenue and to fund our continuing technology development efforts.

To Find out the inside Scoop on BIEI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

BIEI has been putting out some big press lately starting in October when they announced the signing of a non-binding Letter of Intent (LOI) with Auramedi Farmacêutica Ltda (a Brazilian pharmaceutical company) to enter into discussions to explore forming a possible Joint Venture (JV) in Brazil to develop Premier’s various treatment technologies, and oversee the manufacture and distribution of the drugs and devices in the South American market initially.

The formation of this joint venture is expected to expedite the approval, manufacture, sales and distribution of Premier’s proprietary treatments. A third party has projected annual sales, in South America, for Premier’s treatments at $400M by the year 2020.

On December 8 BIEI announced one of the lead outside scientists working on their sponsored research has been invited to present his findings on the treatment of breast cancer, at an evening educational session sponsored by prIME Oncology, at the San Antonio Breast Cancer Symposium December 9, 2015.

Researchers have previously presented positive results from the application of breast cancer antibodies along with Premier Biomedical’s technology in duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego in April, 2014. These results showed statistically significant improvements in survival and prevention of breast cancer in mice treated with innovative anti-breast cancer treatment versus chemotherapy-only and non-treated groups. Most significantly, the research has shown the prevention of breast cancer metastasis in mice with the jointly developed breast cancer antibody.

We have a Monster Pick Coming. Subscribe Right Now!

Currently exploding up the charts BIEI has minimal assets, no revenues to date and fast rising debt that has led to massive dilution in the past and likely will again in the future; As of November 20, 2015, there were 60,518,737 shares outstanding, going back 1 year; As of November 14, 2014, there were 21,757,175 shares outstanding; that’s 70% of equity lost due to dilution over a 12 month period. BIEI is focused on developing medical treatments for diseases in humans especially the hunt for a cure for cancer where they say they have been making great strides with CEO William A. Hartman stating ”I believe that we have a clear roadmap for potentially curing cancer, possibly at any stage, and even after extensive metastasis.” after they obtained exclusive rights to the recently allowed U.S. patent application, “Sequential Extracorporeal Treatment of Bodily Fluids” I would take this statement with a huge grain of salt; really huge gain of salt. BIEI knows how to market itself with management clearly believing in their own abilities with significant inside buying. We will be updating on BIEI when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with BIEI.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in BIEI either long or short and we have not been compensated for this article.

Share.

1 Comment

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.